Insights from ASH 2025, including anticipated presentations, key takeaways, and how emerging research in paroxysmal nocturnal ...

The US Food and Drug Administration has approved danicopan (Voydeya, AstraZeneca) as an add-on therapy to treat extravascular hemolysis in adults receiving ravulizumab or eculizumab for paroxysmal ...

The approval specifies use of the first-in-class agent with ravulizumab (Ultomiris) or eculizumab (Soliris), standard-of-care treatment for PNH. Anywhere from 10-20% of patients with PNH develop ...

Voydeya is a first-in-class, oral, factor D inhibitor. The Food and Drug Administration (FDA) has approved Voydeya ™ (danicopan) as add-on therapy to ravulizumab or eculizumab for the treatment of ...

The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and lethal disorder of the blood in which the body attacks and destroys red blood cells in massive amounts. This focus collection and short ...

Published Apr 1, 2024 7:00am EDT Approval of first-in-class, oral, Factor D inhibitor based on results from pivotal ALPHA Phase III trial WILMINGTON, Del. -- (BUSINESS WIRE)-- VOYDEYA™ (danicopan) has ...

Basel, June 11, 2021 — Novartis today announced new Phase II data for iptacopan (LNP023), an investigational oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), presented at the 26th Annual ...

From the time of diagnosis in 2004, the patient required an average of 3 units of packed red cells per month until May 2008, when she began to receive eculizumab treatment. After approximately 2 years ...

We apologize, but this video has failed to load. Try refreshing your browser, or tap here to see other videos from our team. A welcome email is on its way. If you don't see it, please check your junk ...

Basel, June 11, 2021 — Novartis today announced new Phase II data for iptacopan (LNP023), an investigational oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), presented at the 26th Annual ...